Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) has earned a consensus rating of “Moderate Buy” from the nine research firms that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and seven have issued a buy recommendation on the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $18.25.

Several research firms have recently weighed in on ADPT. Guggenheim lifted their price objective on Adaptive Biotechnologies from $20.00 to $21.00 and gave the stock a “buy” rating in a research report on Monday, January 26th. Morgan Stanley initiated coverage on Adaptive Biotechnologies in a research note on Monday, December 1st. They set an “equal weight” rating and a $21.00 target price for the company. JPMorgan Chase & Co. lifted their target price on Adaptive Biotechnologies from $20.00 to $21.00 and gave the stock an “overweight” rating in a report on Friday, February 6th. Wall Street Zen lowered Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a research note on Saturday, March 7th. Finally, Piper Sandler set a $21.00 price target on Adaptive Biotechnologies in a report on Friday, February 6th.

Insider Activity at Adaptive Biotechnologies

In other Adaptive Biotechnologies news, insider Harlan S. Robins sold 470,266 shares of Adaptive Biotechnologies stock in a transaction on Wednesday, March 11th. The shares were sold at an average price of $13.17, for a total value of $6,193,403.22. Following the completion of the sale, the insider directly owned 1,522,058 shares of the company’s stock, valued at approximately $20,045,503.86. The trade was a 23.60% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Chad M. Robins sold 470,167 shares of the company’s stock in a transaction dated Wednesday, March 11th. The shares were sold at an average price of $13.17, for a total transaction of $6,192,099.39. Following the transaction, the chief executive officer owned 2,301,113 shares in the company, valued at $30,305,658.21. This represents a 16.97% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 2,422,544 shares of company stock worth $35,397,620 over the last ninety days. 6.40% of the stock is owned by corporate insiders.

Institutional Trading of Adaptive Biotechnologies

Several large investors have recently made changes to their positions in the company. Caitong International Asset Management Co. Ltd acquired a new position in Adaptive Biotechnologies during the 4th quarter worth approximately $28,000. Sound Income Strategies LLC acquired a new stake in Adaptive Biotechnologies in the third quarter valued at approximately $30,000. EverSource Wealth Advisors LLC increased its holdings in shares of Adaptive Biotechnologies by 197.1% during the fourth quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company’s stock valued at $38,000 after acquiring an additional 1,565 shares in the last quarter. Assetmark Inc. increased its holdings in shares of Adaptive Biotechnologies by 867.9% during the fourth quarter. Assetmark Inc. now owns 3,020 shares of the company’s stock valued at $49,000 after acquiring an additional 2,708 shares in the last quarter. Finally, T. Rowe Price Investment Management Inc. acquired a new position in shares of Adaptive Biotechnologies during the fourth quarter worth approximately $51,000. 99.17% of the stock is currently owned by institutional investors and hedge funds.

Adaptive Biotechnologies Stock Up 1.8%

ADPT opened at $14.15 on Thursday. Adaptive Biotechnologies has a twelve month low of $6.68 and a twelve month high of $20.76. The company has a fifty day moving average of $16.03 and a 200-day moving average of $15.91. The stock has a market cap of $2.18 billion, a PE ratio of -35.37 and a beta of 2.19.

Adaptive Biotechnologies (NASDAQ:ADPT) last released its earnings results on Thursday, February 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.10. The business had revenue of $71.68 million for the quarter, compared to analyst estimates of $59.38 million. Adaptive Biotechnologies had a negative net margin of 21.48% and a negative return on equity of 46.68%. Adaptive Biotechnologies’s revenue for the quarter was up 51.0% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.23) earnings per share. Sell-side analysts anticipate that Adaptive Biotechnologies will post -0.92 EPS for the current fiscal year.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.